<DOC>
	<DOCNO>NCT01699464</DOCNO>
	<brief_summary>A double-masked , parallel study AR-12286 Ophthalmic Solution 0.5 % , 0.7 % ( q.d. , PM ) timolol maleate Ophthalmic Solution , 0.5 % ( b.i.d . ) , O.U . 3 month .</brief_summary>
	<brief_title>A Study Assessing Safety Ocular Hypotensive Efficacy AR-12286 Patients With Elevated Intraocular Pressure 3 Months</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . 18 year age great . 2 . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) . 3 . Unmedicated ( postwashout ) IOP ≥ 24 mm Hg 2 eligibility visit ( 0800 hr ) , 27 day apart , ≥ 22 mm Hg 1000 1600 hrs second qualification visit . If one eye meet IOP criterion must eye meet criteria qualification timepoints . 4 . Corrected visual acuity eye +1.0 logMAR good ETDRS eye ( equivalent 20/200 ) . 5 . Able willing give sign informed consent follow study instruction . Ophthalmic 1 . Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure narrow angle . Note : Previous laser peripheral iridotomy NOT acceptable . 2 . IOP &gt; 36 mm Hg 3 . Current use 1 ocular hypotensive medication ( Note : fix dose combination consider multiple medication ) . 4 . Known hypersensitivity component formulation ( benzalkonium chloride , etc . ) , topical anesthetic . 5 . Previous glaucoma intraocular surgery glaucoma laser procedure study eye ( ) . 6 . Refractive surgery study eye ( ) ( e.g. , radial keratotomy , PRK , LASIK , etc. ) . 7 . Ocular trauma within past six month , ocular surgery laser treatment within past three month . 8 . Evidence ocular infection , inflammation , clinically significant blepharitis conjunctivitis baseline ( Visit 1 ) , history herpes simplex keratitis 9 . Ocular medication kind within 30 day Visit 1 , exception ) ocular hypotensive medication ( must wash accord provided schedule ) , b ) lid scrub ( may use prior , Visit 1 ) c ) lubricate drop dry eye ( may use throughout study ) . 10 . Clinically significant ocular disease ( e.g . uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe ( i.e. , cupdisc ratio &gt; 0.8 ) . 11 . Central corneal thickness great 600 µm . 12 . Any abnormality prevent reliable applanation tonometry either eye . Systemic : Systemic : 13 . Clinically significant abnormality ( determine treat physician ) laboratory test screen . 14 . Known hypersensitivity contraindication beta adrenoceptor antagonists include chronic obstructive pulmonary disease bronchial asthma ; abnormally low blood pressure heart rate ; second third degree heart block congestive heart failure ; severe diabetes ) . 15 . Clinically significant systemic disease ( e.g. , myasthenia gravis , hepatic , renal , endocrine cardiovascular disorder ) might interfere study . 16 . Participation investigational study within past 30 day . 17 . Changes systemic medication could substantial effect IOP within 30 day prior screen , anticipate study . 18 . Due current status preclinical safety program , woman childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Glaucoma</keyword>
</DOC>